“Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation” (2017) Farmeconomia. Health economics and therapeutic pathways, 18(1). doi:10.7175/fe.v18i1.1327.